December 20, 2019 Plenty of choice remains for buyers of gene therapy Despite the recent flurry of gene therapy deals there is still a fairly extensive list of affordable companies out there.
April 12, 2017 First-quarter floats see haves pulling away from the have-nots Demand for new issues remains sluggish - only eight private biotechs managed to pull off an IPO in the first quarter of 2017.
